Bristol-Myers Squibb stock
BMYNYSEBristol-Myers Squibb Company, HealthcareISIN US1101221083
70Score 70 out of 100, Strong
Price and trend
81 / 100
Price history
+27% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 3.4% above it.
Since December 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 54).
The price is 8.5% below its 52-week high. Largest decline in 20 years: 51% (December 2022 to July 2024).
Chart figures for advanced users
- SMA 50$61.99
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$60.29
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)54
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$45.79
- The lowest closing price of the last twelve months.
- Resistance$68.09
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Bristol-Myers Squibb Company belongs to the Drug Manufacturers (General) industry (United States) and, with a market value of $127.39B, is number 12 of 27 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $50.15B (up 4.1%) and adjusted earnings per share of $6.44 (up 4.7%).
- MEQIRI Score 70 out of 100 (Strong): rank 128 of 702 in Healthcare, median 53.
Show more
- The P/E is 13.8 (Drug Manufacturers (General) median 25.7, own median of recent years 20.8).
- Our model puts fair value at $90.24, with the price 31% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for over 54 years.Capital allocation 55
- Modestly valuedP/E 13.8, Drug Manufacturers (General) median 25.7, own median 20.8.Valuation 86
- Below fair valuePrice 31% below the fair value of $90.24.Valuation 86
Weaknesses
- High debtDebt 1.91 times equity (latest quarter), Drug Manufacturers (General) median 1.2.Stability 59
- Analysts expect falling earningsDown 6.3% a year through 2028 (estimates from 16 analysts).Growth 38
- Margin may fall backOperating margin 28.5%, average of the prior years 18.2%, which ranged from 5.1% to 19.7%. After peaks like this, the margin was more than a quarter lower two years later in 44 of 100 cases, against 24 of 100 for other companies with high margins.
Its standout strengths are profitability and valuation, while growth holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 71 to 70.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $69.41 and expensive above $128.91 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $64.68 (cash-flow model) and $115.80 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $85.40, at 7.8% it would be $97.46.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (25.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 4.2% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 71%, operating 28%, net 15%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 4 Feb 2027in 83 days
- Last reported
- 29 Oct 2026EPS reported $1.35 (expected $1.10)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $6.44+1.9%
- Revenue
- $50.15B+0.5%
- Earnings per share
- $6.69+1.1%
- Revenue
- $48.78B+0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +3.2%Bristol-Myers Squibb raised its 2026 full year guidance again, with higher expected revenue and non-GAAP EPS now at $6.35 to $6.55.
“After including the $0.58 per share previously referenced, our expected non GAAP EPS guidance range for 2026 is now $6.35 to $6.55 We are maintaining our projections for gross margin, operating expenses, and tax rate while slightly lowering the expense level on our other income and expense line.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $677,826 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Bristol-Myers Squibb
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- AmgenAMGN $252.64B76
- Gilead SciencesGILD $208.31B57
- Novo NordiskNOVO-B.CO $180.19B79
- PfizerPFE $164.33B60
- SanofiSAN.PA $116.8B67
- GSKGSK $101.51B69
- Chugai Pharmaceutical4519.T $73.66B78
- BayerBAYN.DE $61.57B53
ETFs that hold Bristol-Myers Squibb
Held by 148 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| WisdomTree US High Dividend UCITS ETF AccWTD9 | 3.77% | 0.29% | €182.46M |
| WisdomTree US Equity Income UCITS ETF EUR Hedged AccWTDY | 3.68% | 0.35% | €204.34M |
| VanEck Morningstar US ESG Wide Moat UCITS ETFGMVM | 2.77% | 0.49% | €375.33M |
Show 5 more
| VanEck Morningstar Developed Markets Dividend Leaders UCITS ETFVDIV | 2.22% | 0.38% | €10.62B |
| Invesco S&P 500 High Dividend Low Volatility UCITS ETFHDLV | 2.03% | 0.30% | €361.04M |
| iShares MSCI USA Quality Dividend Advanced UCITS ETFQDVD | 1.94% | 0.35% | €794.64M |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 1.93% | 0.15% | €599.59M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 1.88% | 0.15% | €3.29B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 11 Nov 2026, previously Neutral
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.